518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers

MLA

Panagiotis Kourtesis, et al. “518 Phase 1B Trial of Monalizumab (NKG2A Inhibitor) plus Durvalumab: Safety and Efficacy in Patients with Metastatic Ovarian, Cervical, and Microsatellite-Stable Endometrial Cancers.” Ovarian Cancer, Dec. 2020. EBSCOhost, https://doi.org/10.1136/ijgc-2020-esgo.147.

APA

Panagiotis Kourtesis, Inmaculada Sanchez-Simon, Sandip Pravin Patel, Mayukh Das, Susana Banerjee, Alfonso Cortés Salgado, Jennifer R. Diamond, Maria Libera Ascierto, Amit M. Oza, & Ana Oaknin. (2020). 518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers. Ovarian Cancer. https://doi.org/10.1136/ijgc-2020-esgo.147

Chicago

Panagiotis Kourtesis, Inmaculada Sanchez-Simon, Sandip Pravin Patel, Mayukh Das, Susana Banerjee, Alfonso Cortés Salgado, Jennifer R. Diamond, Maria Libera Ascierto, Amit M. Oza, and Ana Oaknin. 2020. “518 Phase 1B Trial of Monalizumab (NKG2A Inhibitor) plus Durvalumab: Safety and Efficacy in Patients with Metastatic Ovarian, Cervical, and Microsatellite-Stable Endometrial Cancers.” Ovarian Cancer, December. doi:10.1136/ijgc-2020-esgo.147.